This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.
William Busse, MD
Advertisement
Articles by William Busse, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
First Half 2026 Recap: Dermatology
2
From Red-Cheeked Baby to Bulbous Nose: Rosacea, Start to Finish
3
Guideline-Directed Care Improves Limb Outcomes in Peripheral Artery Disease
4
Navigating a New Era of PH Management as an APP, With Susanne McDevitt, DNP
5